Client Story
How PHM supported Susan with advanced treatments and adaptive strategies for metastatic breast cancer.
Susan, a 58-year-old wife and mother with a passion for travel and gardening, faced a devastating recurrence of breast cancer six years after completing treatment for early-stage disease. Her cancer had metastasized to her liver, ovaries, bowel, and bones, making it incurable. Despite care from a top specialist, her condition worsened, prompting Susan to seek guidance from Private Health Management.
Over the years, PHM guided Susan through a series of advanced treatments, including early access to drugs that would later receive FDA approval for her specific subtype of breast cancer. By leveraging advanced molecular profiling and liquid biopsy technology, her Personal Care Team tailored her treatments to the evolving characteristics of her cancer.
PHM facilitated Susan’s enrollment in clinical trials that offered novel targeted therapies, immunotherapies, and antibody-drug conjugates. She became one of the first patients with HER2-low breast cancer to receive Enhertu, a groundbreaking HER2-targeting antibody drug conjugate now FDA-approved for this type of cancer.
PHM’s proactive approach ensured that Susan consistently accessed innovative treatments as they became available.
Susan lived with metastatic breast cancer for 13 years, highlighting the impact of adaptive strategies and state-of-the-art treatments on quality of life and longevity. PHM is commited to personalized care, advanced diagnostics, and relentlessly pursuing life-extending therapies.
Empower your patient journey by gathering insights from our Cancer Survivability whitepaper.
Discover our Why Wall
